32618-84-1

Basic information

• Product Name: 6-METHOXYQUINAZOLINE-2,4-DIOL
• Synonyms: 6-METHOXYQUINAZOLINE-2,4-DIOL;6-Methoxy-1,2,3,4-tetrahydroquinazoline-2,4-dione;6-Methoxyquinazoline-2,4(1H,3H)-dione;6-Methoxy-2,4(1H,3H)-quinazolinedione;6-methoxy-1H-quinazoline-2,4-dione
• CAS NO: 32618-84-1
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.18
• Mol File: 32618-84-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: >270℃
• Appearance: /
• Density: 1.322±0.06 g/cm3(Predicted)
• PKA: 10.83±0.20(Predicted)
• CAS DataBase Reference: 6-METHOXYQUINAZOLINE-2,4-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXYQUINAZOLINE-2,4-DIOL(32618-84-1)
• EPA Substance Registry System: 6-METHOXYQUINAZOLINE-2,4-DIOL(32618-84-1)

Safety Data

• Hazardous Substances Data: 32618-84-1(Hazardous Substances Data)

Usage

General Description

6-Methoxyquinazoline-2,4-diol is a chemical compound that belongs to the quinazoline class of organic compounds. It is a derivative of quinazoline with a methoxy group at the 6-position and hydroxy groups at the 2- and 4-positions. 6-Methoxyquinazoline-2,4-diol is a potential intermediate in the synthesis of pharmaceuticals and other organic compounds. It has been studied for its potential biological and pharmacological activities, including antiviral and antitumor properties. Additionally, 6-Methoxyquinazoline-2,4-diol may have applications in the development of new drugs and materials.

Upstream product

• 23842-82-2 2-amino-5-methoxybenzonitrile 
• 57-13-6 urea 
• 4294-95-5 4-methoxyanthranilic acid 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 124-38-9 carbon dioxide 
• 201230-82-2 carbon monoxide 
• 41994-92-7 2-nitro-5-methoxybenzamide 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 590-28-3 potassium cyanate 
• 1882-70-8 2-amino-5-methoxybenzoic acid hydrochloride 

Downstream Products

• 1313892-51-1 C₂₀H₁₅BrN₄O 
• 1313891-20-1 4-(4-chlorophenyl)-N-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-yl)thiazol-2-amine 
• 62484-31-5 2,4,-dichloro-7-methoxyquinazoline 
• 1313892-57-7 C₂₃H₁₆FN₅OS*ClH 
• 1313892-07-7 C₂₂H₁₅FN₆OS*ClH 
• 1313890-36-6 C₂₀H₁₃Cl₂N₃O₂*ClH 
• 1036755-97-1 2-chloroquinazolin-6-ol 
• 952434-87-6 2-chloro-6-methoxy-4-methyl-quinazoline 
• 850424-11-2 2-chloro-6-methoxyquinazoline 

Relevant articles and documents

Method for preparing 2,4-(1H,3H)-quinazoline diketone compound

The invention discloses a method for preparing a 2,4-(1H,3H)-quinazoline diketone compound. A 2-aminobenzonitrile compound as shown in a formula (1) and carbon dioxide are used as raw materials and react in 2-hydroxypyridine ionic liquid to obtain the 2,4-(1H,3H)-quinazoline diketone compound as shown in a formula (II), and the reaction formula is as shown in the specification. When the ionic liquid is applied to the reaction for preparing the 2,4-(1H,3H)-quinazoline diketone compound, the reaction condition is mild, the separation and purification process of the product is simple, the product yield is high, and the substrate application range is wide.

Facile and efficient synthesis of quinazoline-2,4(1H,3H)-diones through sequential hydrogenation condensation

The heterocyclizations from various methyl (2-nitrobenzoyl)carbamates to substituted quinazoline-2,4(1H,3H)-diones under hydrogenation conditions were investigated in this study. In the presence of p-toluenesulfonic acid monohydrate in methanol, various q

The therapeutic compound, use and related method (by machine translation)

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing a compound or its salt which prevents or treats a central nervous system disease in which integration dysfunction syndrome and agnosia are enumerated as exemplary disorders.SOLUTION: The pharmaceutical composition includes the compound or its salt represented by chemical formula (A) which modulates striatal-enriched protein tyrosine phosphatase (STEP).